초록

The present invention relates to compound of Formula III comprising an amino acid component, a divalent metal component, and a counter-ion component, compositions containing same, and methods of use.

대표청구항 ▼

1. A compound of Formula III having an amino acid component, which consists of two amino acids coordinated around a divalent metal cation, a metal component, which consists of a divalent metal cation, and a counter-ion component, which consists of one or two additional molecules, A and B, ionically

1. A compound of Formula III having an amino acid component, which consists of two amino acids coordinated around a divalent metal cation, a metal component, which consists of a divalent metal cation, and a counter-ion component, which consists of one or two additional molecules, A and B, ionically bound to the amino acid component, whereinR1 and R2 are the same or different and each is a side chain of an amino acid coordinated around X;X1 and X2 are H;X is selected from magnesium (Mg2+), calcium (Ca2+), or Zinc (Zn2+) as the metal component;A and B are each an omega-3 fatty acid, A and B are the same or different, and B is present or absent; andwherein B is present and A and B are independently selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA). 2. The compound of claim 1, wherein R1 and R2 are the same and selected from lysine or arginine amino acid side chains. 3. A composition comprising the compound of claim 2, and a carrier. 4. The composition of claim 3, wherein the composition comprises a mixture of two or more of the compounds in a single dosage form. 5. The composition of claim 4, wherein the composition is a pharmaceutical or nutriceutical composition and the carrier is acceptable for administration to humans. 6. The composition of claim 5, wherein the composition is a pharmaceutical composition. 7. The composition of claim 6, wherein the mixture comprises a first compound and a second compound. 8. The composition of claim 7, wherein A and B in each of the first and second compounds are independently selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA). 9. The composition of claim 8, wherein A and B are the same in each of the first second compounds, but different between the two compounds. 10. The composition of claim 9, wherein R1 and R2 are both lysine side chains. 11. The composition of claim 10, wherein X is magnesium. 12. The composition of claim 11, wherein A and B are both EPA in the first compound and A and B are both DHA in the second compound. 13. The composition of claim 12, wherein the first and second compounds are present in the composition in a weight ratio of from 1.25:1 to 4:1, or a ratio of 2:1, 3:1, or 5:4. 14. The composition of claim 13, further comprising an additional API or therapeutic agent in the same dosage form. 15. The composition of claim 14, wherein the API or therapeutic agent is an antihyperlipidemic agent. 16. The composition of claim 15, wherein the antihyperlipidemic agent is a statin, a cholesterol absorption inhibitor, a CETP inhibitor, or a pharmaceutically-acceptable salt or prodrug thereof. 17. The composition of claim 16, wherein the antihyperlipidemic agent is a statin. 18. The composition of claim 17, wherein the statin is selected from the group consisting of atorvastatin, risuvostatin, simvastatin, pravastatin, or a pharmaceutically acceptable salt or prodrug thereof. 19. The composition of claim 18, wherein the composition comprises an amount each of the compounds of Formula III effective to lower elevated serum triglycerides in a subject and an amount of the statin effective to lower serum cholesterol in the subject. 20. The composition of claim 19, wherein the subject is a human subject having severe hypertriglyceridemia. 21. The composition of claim 3 or 4, wherein the composition is a pharmaceutical composition and comprises an amount of a compound or compounds effective to treat insulin resistance, pre-diabetes, hypertriglyceridemia, dyslipidemia, fatty liver, or obesity in a subject, preferably a human subject. 22. The composition of claim 3 or 4, wherein the composition is a pharmaceutical composition and comprises an amount of a compound or compounds effective to treat a disease or disorder selected from the group consisting of arthritis, irritable bowel syndrome, atrial fibrillation, ophthalmic inflammation disorders, dry eye syndrome, traumatic brain injury, familial adenomatous polyposis, sporadic adenomatous polyposis, epilepsy, epileptic syndrome, Alzheimer's disease, and attention deficit hyperactivity disorder (ADHD). 23. The composition of claim 3 or 4, wherein the composition is a pharmaceutical composition and comprises an amount of a compound or compounds effective to treat or manage pain in a subject. 24. The composition of claim 23, wherein the additional therapeutic agent is gabapentin. 25. The composition of claim 23, wherein the additional therapeutic agent is a non-steroidal anti-inflammatory agent. 26. A package or kit comprising a unit dosage form of the composition of claim 3 or 4, at least one container for holding the unit dosage forms, and instructions for use. 27. A method of treating a disease or disorder in a subject, preferably a human subject, the method comprising administering to the subject an amount of the composition of claim 3 or 4 effective to treat the disease or disorder in the subject, the disease or disorder selected from the group consisting of hypertriglyceridemia, severe hypertriglyceridemia, pre-diabetes, fatty liver disease, obesity, arthritis, irritable bowel syndrome, atrial fibrillation, ophthalmic inflammation disorders, dry eye syndrome, traumatic brain injury, familial adenomatous polyposis, sporadic adenomatous polyposis, epilepsy, epileptic syndrome, Alzheimer's disease, pain of neuropathic or nociceptive origin, and attention deficit hyperactivity disorder (ADHD).